Appropriate timing for a biochemical evaluation after adrenalectomy for unilateral aldosterone-producing adenoma.


Journal

Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653

Informations de publication

Date de publication:
06 2020
Historique:
received: 27 12 2019
revised: 01 02 2020
accepted: 04 02 2020
pubmed: 19 2 2020
medline: 19 8 2021
entrez: 19 2 2020
Statut: ppublish

Résumé

The oversecretion of plasma aldosterone by unilateral aldosterone-producing adenoma (APA) can be cured by adrenalectomy. However, the time needed for the endocrine environment to normalize remains unclear. To clarify adequate timing for a biochemical evaluation in unilateral APA patients after adrenalectomy. A total of 166 unilateral APA patients were retrospectively reviewed. We evaluated the plasma aldosterone concentration (PAC) (pg/mL), active renin concentration (ARC) (pg/mL), aldosterone-renin ratio (ARR; PAC/ARC), serum potassium concentration and estimated glomerular filtration rate (eGFR) at 1, 3 and 6 postoperation months (POM). PAC was significantly lower at 1POM than at presurgery (presurgery; 407.2, 1 POM; 90.0 pg/mL, P < .001). ARC did not increase from baseline at 1POM, but significantly increased at 3POM (presurgery; 4.43, 1POM; 4.87, 3POM; 11.3 pg/mL, P < .001). ARR significantly decreased at 1POM (presurgery; 146.9, 1 POM; 26.3, P < .001) although ARC did not increase at 1POM. Among the 34 patients who had hypokalaemia presurgery, it was resolved in 28 (82%) at 1POM and in all (100%) at 3POM. The biochemical outcomes at 1POM were 131 (79%) complete, 20 (12%) partial and 15 (9%) absent successes, while at 3POM, 147 (89%) were complete, 9 (5%) partial and 10 (6%) absent. Twenty-three (14%) patients were reclassified into different biochemical outcomes between 1 and 3POM, whereas only 5 (3%) changed between 3 and 6POM. The appropriate timing for a biochemical evaluation of unilateral APA patients treated with laparoscopic adrenalectomy appears to be 3 months or more after surgery.

Identifiants

pubmed: 32068902
doi: 10.1111/cen.14176
doi:

Substances chimiques

Aldosterone 4964P6T9RB

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

503-508

Informations de copyright

© 2020 John Wiley & Sons Ltd.

Références

Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916.
Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-1248.
Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-2300.
Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811-1820.
Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M, Favia G. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg. 2005;71(10):864-869.
Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689-699.
Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711-721.
Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982-992.
Starker LF, Christakis I, Julien JS, et al. Considering postoperative functional hypoaldosteronism after unilateral adrenalectomy. Am Surg. 2017;83(6):598-604.
Burrello J, Burrello A, Stowasser M, et al. The primary aldosteronism surgical outcome score for the prediction of clinical outcomes after adrenalectomy for unilateral primary aldosteronism. Ann Surg 2019. https://doi.org/10.1097/SLA.0000000000003200. [Epub ahead of print].
Swearingen AJ, Kahramangil B, Monteiro R, et al. Analysis of postoperative biochemical values and clinical outcomes after adrenalectomy for primary aldosteronism. Surgery. 2018;163(4):807-810.
Byrd JB, Turcu AF, Auchus RJ. Primary aldosteronism. Circulation. 2018;138(8):823-835.
Damkjaer M, Isaksson GL, Stubbe J, Jensen BL, Assersen K, Bie P. Renal renin secretion as regulator of body fluid homeostasis. Pflugers Archiv. 2013;465(1):153-165.
Kim IY, Park IS, Kim MJ, et al. Change in kidney function after unilateral adrenalectomy in patients with primary aldosteronism: identification of risk factors for decreased kidney function. Int Urol Nephrol. 2018;50(10):1887-1895.
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72(3):658-666.
Stowasser M, Gordon RD. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. Physiol Rev. 2016;96(4):1327-1384.
Young JrWF. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology. 2003;144(6):2208-2213.

Auteurs

Kimiharu Takamatsu (K)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Toshikazu Takeda (T)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Seiya Hattori (S)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Nobuyuki Tanaka (N)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Shinya Morita (S)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Kazuhiro Matsumoto (K)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Takeo Kosaka (T)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Ryuichi Mizuno (R)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Toshiaki Shinojima (T)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Eiji Kikuchi (E)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Hiroshi Asanuma (H)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Isao Kurihara (I)

Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Hiroshi Itoh (H)

Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Mototsugu Oya (M)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH